Peptivius / Blueprint / Home
Weight Loss.
7 peptides, ranked.
Weight Loss is the metabolic layer of the Blueprint: appetite, satiety, glucose handling, body composition, lean-mass preservation, and the practical work of keeping weight loss sustainable. Each candidate was evaluated against your BioProfile, training load, and declared contraindications. The strongest matches sit at the top; secondary options remain visible for comparison.
01 /
Ranked list
| Rank | Peptide | Match | Evidence | Regimen | |
|---|---|---|---|---|---|
| 01 |  Tirzepatide mounjaro - zepbound | 91 | +Afda approved | subcutaneous - label escalation context | View |
| 02 |  Semaglutide ozempic - wegovy | 88 | +Afda approved | subcutaneous - label escalation context | View |
| 03 |  Retatrutide ly3437943 | 86 | +A-phase 3 | subcutaneous - trial context only | View |
| 04 |  Tesamorelin egrifta | 74 | ~Bfda approved | subcutaneous - approved-indication context | View |
| 05 |  Liraglutide saxenda - victoza | 70 | +B+fda approved | subcutaneous - label escalation context | View |
| 06 |  Sermorelin ghrh 1-29 | 64 | xCcompoundable cat 1 | subcutaneous - variable clinical context | View |
| 07 |  CagriSema cagrilintide + semaglutide | 62 | +A-phase 3 | subcutaneous - pipeline trial context | View |
02 /
Category comparison matrix
Category education
This matrix compares the Weight Loss peptides as category education. It is not a medical ranking and does not replace your Match Score. The goal is to separate established options, investigational candidates, and adjacent body-composition compounds.
| Peptide | Regulatory anchor | Mechanism | Weight-loss role | Evidence maturity | Readiness | Watchout | Takeaway |
|---|---|---|---|---|---|---|---|
Tirzepatide tirzepatide | Zepbound for chronic weight management; Mounjaro is diabetes context. | Dual GLP-1 / GIP agonist. | High-efficacy appetite, weight, and metabolic anchor. | High: approved label plus large clinical programs. | High when evaluated through regulated care. | GI tolerance, gallbladder/pancreatitis, kidney volume depletion, lean mass, MTC/MEN2, oral contraceptive/procedure disclosure. | One of the strongest current approved anchors, but not automatically right for everyone. |
Semaglutide semaglutide | Wegovy injection/tablet for weight management; Ozempic is diabetes context. | GLP-1 receptor agonist. | Mature benchmark for appetite, satiety, weight, and glucose context. | High: one of the best-established GLP-1 references. | High, but product/formulation/label matters. | GI/gastroparesis, gallbladder/pancreatitis, kidney volume depletion, retinopathy in diabetes, heart rate, procedure disclosure. | The category benchmark: familiar, mature, and useful for comparison. |
Retatrutide retatrutide | Investigational obesity trials; no approved label. | Triple GLP-1 / GIP / glucagon agonist. | Future-facing high-ceiling metabolic candidate. | Promising but investigational: strong phase 2, phase 3 context still maturing. | Low outside clinical trials. | Not approved, no consumer label, not a compounding-equivalent pathway, long-term safety/access unsettled. | Watchlist compound, not a use plan today. |
Tesamorelin tesamorelin | Egrifta WR/SV for HIV-associated lipodystrophy abdominal fat. | GHRH / GH / IGF-1 axis. | Adjacent body-composition/visceral-fat context, not appetite-first weight loss. | Good in narrow indication; limited for broad obesity. | Medium/low for broad Weight Loss. | IGF-1, glucose, edema/carpal-tunnel-like symptoms, malignancy/endocrine review, indication mismatch. | Legitimate but narrow; not a GLP-1 replacement. |
Liraglutide liraglutide | Saxenda for chronic weight management; Victoza is diabetes context. | Daily GLP-1 receptor agonist. | Established older GLP-1 option with lower modern convenience. | Established, but lower current category ceiling than weekly incretins. | Medium: approved, but daily burden matters. | Daily adherence, GI, gallbladder/pancreatitis, kidney volume depletion, MTC/MEN2, procedure disclosure. | Approved and familiar, usually a secondary comparator in modern Weight Loss. |
Sermorelin sermorelin | Variable GH-axis clinical context; no obesity label. | GHRH 1-29 / GH-axis support. | Indirect recovery, sleep, lean-mass/body-composition context. | Weak for direct Weight Loss. | Low as a primary weight-loss tool. | No universal protocol, IGF-1/glucose monitoring, edema, sleep apnea, malignancy/endocrine review, compounding quality. | May belong more to recovery/body composition than primary Weight Loss. |
CagriSema cagrisema | Pipeline combination: cagrilintide + semaglutide in REDEFINE context. | Amylin + GLP-1. | Future multi-pathway satiety category. | Promising late-stage, but label/post-market profile not settled. | Low until approval and label. | Not semaglutide alone, not a DIY stack, not a compounded blend, cagrilintide compounding/legal risk. | Important for understanding where the category is heading, not for replacing approved options now. |
Not a protocol
Approved, promising, and high-match mean different things. Approved products apply to specific labels, indications, and presentations. Investigational compounds are not consumer protocols. Compounded, research-only, grey-market, or "not for human consumption" products are not equivalent to approved medications.
03 /
Combination & Overlap Map
Overlap map
This table shows combinations users often encounter in Weight Loss research. It does not recommend stacks. The goal is to explain differences between a formal product, an attempt to recreate a combination, mechanism overlap, switch paths, and combinations that require professional review.
| Combination | Components | Type | Why it appears | Peptivius read | Main caution | Status |
|---|---|---|---|---|---|---|
CagriSema | Cagrilintide + Semaglutide | Formal combination in development | Combines GLP-1 with amylin to broaden satiety signaling. | Pipeline product/combo; useful for understanding the future of the category. | Not semaglutide alone; final label, approval, and access still matter. | Watchlist / category education |
"DIY CagriSema" | Separate semaglutide + cagrilintide | Attempt to recreate a pipeline product | Users may try to assemble the combination outside a regulated product. | Not equivalent to CagriSema and not a substitute. | Quality, exposure accuracy, safety, and regulatory status do not equal trial/formal product context. | Do not recreate |
Tirzepatide + semaglutide | GLP-1/GIP + GLP-1 | Incretin overlap | The idea that two incretins mean more weight loss. | Mechanisms overlap and reduce clarity of benefit/side effect attribution. | GI burden, low intake, dehydration, hypoglycemia risk with some drugs, unclear causality. | Redundant / professional review |
Tirzepatide + liraglutide | GLP-1/GIP + daily GLP-1 | Incretin overlap | May appear because of access, transition, or label confusion. | Should not be read as a stack; at most a switch/transition discussion. | Daily + weekly incretin increases complexity and overlap. | Do not treat as stack |
Retatrutide + any GLP-1/GIP/amylin | Triple agonist + another incretin | Multi-incretin overlap | Retatrutide has high-ceiling hype. | Retatrutide already targets multiple pathways; layering reduces interpretability. | Investigational; research-only is not trial-equivalent; GI and long-term safety still maturing. | Avoid / pipeline only |
Semaglutide to Tirzepatide | GLP-1 to GLP-1/GIP | Switch path, not blend | Users with GLP-1 plateau look for a next step. | Switch can be a clinical topic, but not simultaneous combination. | History of prior exposure, tolerance, indication, and access need review. | Switch discussion |
Incretin + tesamorelin | Tirzepatide/semaglutide + tesamorelin | Appetite/metabolic + GH-axis body composition | Combines weight-loss interest with visceral-fat/body-composition interest. | Advanced discussion; tesamorelin is not appetite-first or broad obesity medicine. | IGF-1, glucose, edema, malignancy/endocrine history, heavier monitoring. | Adjacent / professional review |
Incretin + sermorelin | GLP-1/GIP agent + sermorelin | Appetite/metabolic + GH-axis support | Users seek lean mass, sleep, or recovery support. | Direct Weight Loss evidence for sermorelin is weak and may distract from the main driver. | IGF-1, glucose, sleep apnea, edema, variable compounding quality. | Secondary / caution |
Tesamorelin + sermorelin | Two GH-axis paths | GH/IGF-1 overlap | The idea of amplifying body-composition effects. | Mechanistic overlap; not a casual combination. | IGF-1, glucose, edema, sleep apnea, malignancy/endocrine history. | Redundant / not casual |
Incretin + protein/resistance training | Not a peptide blend | Non-pharmacologic foundation | Lean mass and maintenance are real GLP-1 bottlenecks. | Safest synergy to communicate: support strategy, not peptide stack. | Does not replace clinical monitoring; low intake still matters. | Support foundation |
Combination caution
More mechanisms do not automatically mean better outcomes. In Weight Loss, layering appetite suppressants, incretins, or GH-axis peptides can increase risk, reduce clarity, and make monitoring harder. This table is educational and does not recommend combinations.
04 /
Frequent questions about Weight Loss combinations
Is the table suggesting that I combine peptides?
No. The table explains combinations users encounter in research, forums, market protocols, or pipelines. It separates formal products, mechanism overlap, switch paths, and higher-risk combinations. It is not a use recommendation.
Is CagriSema just semaglutide with cagrilintide?
No. CagriSema is a formal combination in development, with its own product, study design, and regulatory context. Trying to recreate it with separated components is not equivalent.
Can two GLP-1 or incretin agents be used together?
The report does not recommend this. Combining incretins can create mechanism overlap, more gastrointestinal effects, lower food intake, and less clarity about which compound caused benefit or side effect. This requires professional review.
Is switch the same as stack?
No. A switch is a conversation about changing or transitioning between options, usually because of tolerance, response, access, or indication. A stack means simultaneous use. The report separates those concepts.
Do tesamorelin or sermorelin enter to preserve lean mass?
They may appear in body-composition or GH-axis discussions, but they are not appetite peptides and are not first-line broad Weight Loss tools. They require more care around IGF-1, glucose, edema, sleep apnea, and endocrine context.
Why do protein and resistance training appear if they are not peptides?
Because in Weight Loss, especially with GLP-1/incretin agents, preserving lean mass and maintaining protein intake are central to sustainability. This is a support strategy, not a peptide blend.
Does Match Score change if two peptides seem compatible?
In Slice 1, Match Score evaluates individual peptides. Combinations appear as an educational map of compatibility, redundancy, and caution. They should not be read as a new stack score.
Why does the report not build my full stack?
Because that would turn an educational report into a protocol recommendation. Peptivius ranks individual peptides and explains compatibility, risk, and uncertainty. Any combination decision belongs in a conversation with a licensed professional.